A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease

Trial Profile

A Phase III Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Centre Study to Assess the Efficacy and Safety of Omega-3 Free Fatty Acids (Epanova) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 27 May 2014

At a glance

  • Drugs Omega-3 carboxylic acids (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms EPIC-2
  • Sponsors Tillotts Pharma
  • Most Recent Events

    • 27 May 2014 New trial record
    • 19 Oct 2005
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top